Document Detail


Chemoprevention of 7,12-dimethylbenz[a]anthracene (DMBA)-induced oral carcinogenesis in hamster cheek pouch by topical application of resveratrol complexed with 2-hydroxypropyl-beta-cyclodextrin.
MedLine Citation:
PMID:  19932051     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Oral squamous cell carcinoma (OSCC) develops slowly and it is usually preceded by identifiable oral preneoplastic lesions (OPLs): chemoprevention could be a promising approach. Resveratrol (RV) is a plant-based agent characterized by a strong in vitro antineoplastic action, but this effect has not been clinically confirmed owing to its metabolic inactivation. In order to circumvent this limitation and to improve RV efficacy, it was locally applied and complexed with a protective and solubilising vehicle (2-hydroxypropyl-beta-cyclodextrin, HPbetaCD). The experimentation was performed in vitro on 7,12-dimethylbenz[a]anthracene-induced hamster OSCC cell line (HCPC I) and in vivo in the related animal model, by comparison of two RV-HPbetaCD formulations (cream and mouthwash) and RV alone. Vehicles and RV-formulations were free from toxicity. Antiproliferative action of RV on HCPC I was concentration- and time-dependent, and was improved in HPbetaCD-formulations. In vivo, RV prevented OPL and OSCC appearance and growth. Here, too, HPbetaCD-formulations (mainly mouthwash) demonstrated the best chemopreventive effects in terms of lesions prevalence, multiplicity, dimension, and histological signs of malignancy. HPLC detection of RV corroborated that its action is concentration-correlated and is improved by its inclusion in HPbetaCDs. In summary, our study demonstrates that RV is effective in the chemoprevention of DMBA-induced oral carcinogenesis and when it is complexed with HPbetaCDs its efficacy is significantly improved.
Authors:
Giovanni Nicolao Berta; Paolina Salamone; Andrea Elio Sprio; Federica Di Scipio; Lucy Marcela Marinos; Simona Sapino; Maria Eugenia Carlotti; Roberta Cavalli; Francesco Di Carlo
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2009-11-20
Journal Detail:
Title:  Oral oncology     Volume:  46     ISSN:  1879-0593     ISO Abbreviation:  Oral Oncol.     Publication Date:  2010 Jan 
Date Detail:
Created Date:  2010-02-04     Completed Date:  2011-03-28     Revised Date:  2014-07-31    
Medline Journal Info:
Nlm Unique ID:  9709118     Medline TA:  Oral Oncol     Country:  England    
Other Details:
Languages:  eng     Pagination:  42-8     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
9,10-Dimethyl-1,2-benzanthracene
Administration, Topical
Animals
Anticarcinogenic Agents / administration & dosage*,  chemistry
Carcinogens
Carcinoma, Squamous Cell / chemically induced,  prevention & control*
Cell Line, Tumor
Cell Transformation, Neoplastic* / chemically induced
Cheek
Cricetinae
Drug Combinations
Mesocricetus
Mouth Neoplasms / chemically induced,  prevention & control*
Pharmaceutical Vehicles / administration & dosage,  chemistry
Stilbenes / administration & dosage*,  chemistry
beta-Cyclodextrins / administration & dosage*,  chemistry
Chemical
Reg. No./Substance:
0/Anticarcinogenic Agents; 0/Carcinogens; 0/Drug Combinations; 0/Pharmaceutical Vehicles; 0/Stilbenes; 0/beta-Cyclodextrins; 57-97-6/9,10-Dimethyl-1,2-benzanthracene; 94035-02-6/2-hydroxypropyl-beta-cyclodextrin; Q369O8926L/resveratrol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Zebrafish K5 promoter driven GFP expression as a transgenic system for oral research.
Next Document:  Probing the binding of fluoxetine hydrochloride to human serum albumin by multispectroscopic techniq...